PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
BOSTON, May 18, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced...
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics